Stock COPN COSMO PHARMACEUTICALS N.V.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Cosmo Pharmaceuticals N.V.

Equities

COPN

NL0011832936

Market Closed - Swiss Exchange
Other stock markets
 11:30:44 2024-05-03 am EDT 		5-day change 1st Jan Change
72.2 CHF +0.84% Intraday chart for Cosmo Pharmaceuticals N.V. +0.84% +41.85%
Apr. 26 Cosmo Pharmaceuticals N.V. Announces Executive Changes at the Upcoming Annual General Meeting on 24 May 2024 CI
Apr. 25 Cosmo Pharmaceuticals Names New CEO, Chairman MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Cosmo Has Received Approval of an Extension in Respect of the Publication and the Filing of Its Annual Report 2023
NE
Cosmo Pharmaceuticals N : has received approval of an extension in respect of the publication and the filing of its annual report 2023
PU
Cosmo Announces Leadership Changes
NE
Cosmo and Medtronic unveil the future of AI in GI, Genius Summit 2024 reveals innovations and collaborations that advance endoscopic care
AQ
Cosmo and Medtronic Unveil the Future of AI in GI: Genius Summit 2024 Reveals Innovations and Collaborations That Advance Endoscopic Care
NE
Cosmo and Medtronic unveil the future of AI in GI: Genius Summit 2024 reveals innovations and collaborations that advance endoscopic care
PU
Cosmo Pharmaceuticals N : ESG Report 2023
PU
Cosmo Reports Excellent Preliminary Unaudited Full Year 2023 Core Financial Results - Record Guidance for 2024 - Doubles Dividend to 2.00 per Share
NE
Cosmo Pharmaceuticals N : reports excellent preliminary unaudited Full Year 2023 core financial results – Record guidance for 2024 – Doubles dividend to € 2.00 per share
PU
Cosmo Pharmaceuticals Announces Approval of Winlevi(R) in Australia
NE
Cosmo Pharmaceuticals N : announces approval of Winlevi® in Australia
PU
Invitation to Cosmo's Investor Day and Full-Year 2023 Webcast, Zurich, 20 March 2024
AQ
Invitation to Cosmo's Investor Day and Full-Year 2023 Webcast - Zurich, 20 March 2024
NE
Cosmo Pharmaceuticals and Medtronic Forge Ahead in AI-Driven Care
NE
Cosmo confirms full redemption in cash of €175m Convertible Bonds
EQ
Cosmo announces submission of Winlevi® to the European Medicines Agency (EMA)
EQ
Cosmo and Hikma Sign License Agreement for Winlevi® in 17 Middle Eastern and North African Countries
EQ
COSMO AND GLENMARK ANNOUNCE THE SIGNING OF DISTRIBUTION AND LICENSE AGREEMENTS FOR WINLEVI IN EUROPE AND SOUTH AFRICA
AQ
Cosmo and Glenmark announce the signing of Distribution and License Agreements for Winlevi® in Europe and South Africa
EQ
Cosmo Pharmaceuticals N : and Glenmark announce the signing of Distribution and License Agreements for Winlevi® in Europe and South Africaert title here.
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. COPN Stock
  4. News Cosmo Pharmaceuticals N.V.
  5. Press Releases